Abstract
Background While biological age in adults is often understood as representing general health and resilience, the conceptual interpretation of accelerated biological age in children and its relationship to development remains unclear. We aimed to clarify the relationship of accelerated biological age, assessed through telomere length and three omics-derived biological clocks, to child developmental outcomes, including growth and adiposity, cognition, behaviour, lung function and onset of puberty, among European school-age children participating in the HELIX exposome cohort.
Methods The study population included up to 1,173 children, aged between 5 and 12 years, from study centres in the UK, France, Spain, Norway, Lithuania, and Greece. Telomere length was measured through qPCR, blood DNA methylation and gene expression was measured using microarray, and proteins and metabolites were measured by a range of targeted assays. DNA methylation age was assessed using Horvath’s skin and blood clock, while novel blood transcriptome and “immunometabolic” (based on plasma protein and urinary and serum metabolite data) clocks were derived and tested in a subset of children assessed six months after the main follow-up visit. Associations between biological age indicators with child developmental measures as well as health risk factors were estimated using linear regression, adjusted for chronological age, sex, ethnicity and study centre. The clock derived markers were expressed as Δ age (i.e., predicted minus chronological age).
Results Transcriptome and immunometabolic clocks predicted chronological age well in the test set (r= 0.93 and r= 0.84 respectively). Generally, weak correlations were observed, after adjustment for chronological age, between the biological age indicators. Higher birthweight was associated with greater immunometabolic Δ age, smoke exposure with greater DNA methylation Δ age and high family affluence with longer telomere length. All biological age markers were positively associated with BMI and fat mass, and all markers except telomere length were associated with height, at least at nominal significance (p<0.05). Immunometabolic Δ age was associated with better working memory (p = 4e - 3) and reduced inattentiveness (p= 4e -4), while DNA methylation Δ age was associated with greater inattentiveness (p=0.03) and poorer externalizing behaviours (p= 0.01). Shorter telomere length was also associated with poorer externalizing behaviours (p=0.03).
Conclusions In children, as in adults, biological ageing appears to be a multi-faceted process and adiposity is an important correlate of accelerated biological ageing. Patterns of associations suggested that accelerated immunometabolic age may represent build-up of biological capital while accelerated DNA methylation age and telomere attrition may represent a “wear and tear” model of biological ageing in children.
Funding UK Research and Innovation (MR/S03532X/1); European Commission (grant agreement numbers: 308333; 874583)
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by a UKRI Future Leaders Fellowship (MR/S03532X/1). The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 308333 - the HELIX project -, and from the EC's Horizon 2020 research and innovation programme under grant agreement No 874583 - the ATHLETE project. INMA data collections were supported by grants from the Instituto de Salud Carlos III [PI18/00547, PI15/00118 incl. FEDER funds], CIBERESP, and the Generalitat de Catalunya-CIRIT. DSM is a postdoctoral fellow of the Research Foundation Flanders (FWO 12X9620N and 12X9623N). The Norwegian Mother, Father and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. LM was supported by a Juan de la Cierva-Incorporación fellowship (IJC2018-035394-I) awarded by the Spanish Ministerio de Economía, Industria y Competitividad.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Prior to the start of HELIX, all six cohorts had undergone the required evaluation by national ethics committees and obtained all the required permissions for their cohort recruitment and follow-up visits. Each cohort also confirmed that relevant informed consent and approval were in place for secondary use of data from pre-existing data. The work in HELIX was covered by new ethical approvals in each country and at enrolment in the new follow-up, participants were asked to sign a new informed consent form. Additionally, the current study was approved by the Imperial College Research Ethics Committee (Reference: 19IC5567).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to data protection regulations in each participating country and participant data use agreements, human subject data used in this project cannot be freely shared. The raw data supporting the current study are available on request subject to ethical and legislative review. The "HELIX Data External Data Request Procedures" are available with the data inventory in this website: http://www.projecthelix.eu/data-inventory. The document describes who can apply to the data and how, the timings for approval and the conditions to data access and publication. Researchers who have an interest in using data from this project for reproducibility or in using data held in general in the HELIX data warehouse for research purposes can apply for access to data. Interested researchers should fill in the application protocol found in ANNEX I at https://www.projecthelix.eu/files/helix_external_data_request_procedures_final.pdf and send this protocol to helixdata{at}isglobal.org. The applications are received by the HELIX Coordinator, and are processed and approved by the HELIX Project Executive Committee. All code used for data analysis has been provided as supplementary material.
